GHN Pharma Nordic AB, and Welcare Industries SpA, today announced a strategic agreement to launch the Jalosome® line in Denmark,
GHN Pharma Nordic AB is a ”Glocal” Speciality Pharma Company, with priority to original prescription medicines.
The Strategy of GHN Pharma Nordic has two legs; Through its parent company, GHN Pharma International, GHN Pharma Nordic has access to international competence and a Global network. Through the local presence in the Nordic countries, GHN Pharma Nordic is able to incorporate a global outlook and combine this with local demands and requests. Through this strategy GHN Pharma Nordic establish partnerships with global partners for the benefit of the Nordic Health Care market.
Welcare, an Italian company located in the green Umbrian countryside and recently part of the Labomar group, specializes in the eco-sustainable production of a large portfolio of Medical Devices for skin care. A reliable and innovative company, but above all “a company with a story to tell”.From the hospital reality to people’s homes: today, thousands of people all around the world, each one with their own skin type, rely on Welcare for treatment of various skin issues.
Jalosome® Soothing Gel is a Patented Medical Device for the reduction of skin inflammations and related pain due to chemo and radiotherapy, Graft versus Host Disease (GvHD), dermatitis, erythema, and skin disorder of any etiology. 30 - 50 % of patients with cancer undergoes radiotherapy treatment each year and around 95%will have some kind of skin reaction. Most of the new cases of cancer people will be given chemotherapy. 12-35 %, of these patients will have skin reactions for any given chemo.
“We are enthusiastic for the possibility to launch the Jalosome® line in the Nordic. Jalosome® will be an important part in our strategic most important competence area Oncology/Hematology. Once again, we have the opportunity to introduce new and exciting developments within the health care sector”, said Tina Madsen Sandstrőm, CEO of GHN Pharma Nordic AB.
Fulvia Lazzarotto, CEO Welcare Industries S.p.A. “The agreement with GHN Pharma Nordic represents an important achievement for Welcare and underscores our commitment to making Jalosome® available to patients also in the Nordic countries.”